Login / Signup

BclX L (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury.

Olivia J MarolaSarah E R YablonskiPeter G ShragerRobert W NickellsRichard T Libby
Published in: Cell death discovery (2022)
Keyphrases
  • gene therapy
  • spinal cord injury
  • single cell
  • cell therapy
  • optic nerve
  • stem cells